NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
Verastem, Inc.
PeerMedical Ltd.
UMC Utrecht
Assistance Publique - Hôpitaux de Paris
VA Office of Research and Development